Lantern Pharma (LTRN) Depreciation & Amortization (CF) (2019 - 2026)
Lantern Pharma's (LTRN) quarterly Depreciation & Amortization (CF) came in at $3853.0 in Q1 2026, down 15.76% YoY from $4574.0 in Q1 2025, and down 6.09% on a QoQ basis from $4103.0 in Q4 2025.
Lantern Pharma (LTRN) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Lantern Pharma (LTRN) has 8 years of Depreciation & Amortization (CF) data on file, last reported at $3853.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 15.76% year-over-year to $3853.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16559.0 (down 6.95% YoY) and the FY2025 annual result came in at $17280.0, changed 0.01% from the prior year.
- Depreciation & Amortization (CF) fell to $3853.0 in Q1 2026, from $4103.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $4574.0 in Q4 2024 to a low of $1989.0 in Q1 2022.
- A 5-year average of $3712.4 and a median of $3975.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) surged 71.85% — and 2026, when it dropped 15.76%.
- Tracing LTRN's Depreciation & Amortization (CF) over 5 years: stood at $2760.0 in 2022, then jumped by 44.02% to $3975.0 in 2023, then advanced by 15.07% to $4574.0 in 2024, then slipped by 10.3% to $4103.0 in 2025, then slipped by 6.09% to $3853.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $3853.0 (Q1 2026), $4103.0 (Q4 2025), and $4102.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lantern Pharma | 26.05 Mn | 26.05 Mn | - | 3,853.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,853.00 |
| Mar 31, 2026 | 3,853.00 |
| Dec 31, 2025 | 4,103.00 |
| Dec 31, 2025 | 4,103.00 |
| Sep 30, 2025 | 4,102.00 |
| Sep 30, 2025 | 4,102.00 |
| Jun 30, 2025 | 4,501.00 |
| Jun 30, 2025 | 4,501.00 |
| Mar 31, 2025 | 4,574.00 |
| Mar 31, 2025 | 4,574.00 |
| Dec 31, 2024 | 4,574.00 |
| Dec 31, 2024 | 4,574.00 |
| Sep 30, 2024 | 4,389.00 |
| Sep 30, 2024 | 4,389.00 |
| Jun 30, 2024 | 4,258.00 |
| Jun 30, 2024 | 4,258.00 |
| Mar 31, 2024 | 4,061.00 |
| Mar 31, 2024 | 4,061.00 |
| Dec 31, 2023 | 3,975.00 |
| Dec 31, 2023 | 3,975.00 |